Journal
PHARMACEUTICAL RESEARCH
Volume 39, Issue 3, Pages 511-528Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-022-03176-3
Keywords
allometry; cancer treatment; mathematical modeling; microRNA; pharmacokinetics and pharmacodynamics; precision medicine; tumor-immune interaction
Funding
- National Science Foundation [DMS-1930583]
- National Institutes of Health [1R01CA253865, 1U01CA196403, 1U01CA213759, 1R01CA226537, 1R01CA222007, U54CA210181]
- Cockrell Foundation
- Felix L. Haas Endowed Professorship in Basic Science
- NCI [1R01 CA182905-01, 1R01CA222007-01A1]
- NIGMS [1R01GM122775-01]
- DoD [W81XWH2110030]
- Team DOD grant in Gastric Cancer
- Chronic Lymphocytic Leukemia Moonshot Flagship project
- CLL Global Research Foundation 2019 grant
- CLL Global Research Foundation 2020 grant
- Mathers Foundation grant
- Brain SPORE [2P50CA127001]
Ask authors/readers for more resources
The downregulation of miRNA-22 in TNBC is associated with upregulation of eEF2K protein, and miRNA-22 nanotherapy shows potential as an investigational therapeutic agent. A mechanistic model was developed to evaluate the translational potential of miRNA-22 nanotherapy, revealing dose-response relationship and optimal treatment frequency. Combining miRNA-22 nanotherapy with immune checkpoint inhibitors and standard-of-care drugs showed promising results in improving treatment outcomes for TNBC.
Purpose Downregulation of miRNA-22 in triple-negative breast cancer (TNBC) is associated with upregulation of eukaryotic elongation 2 factor kinase (eEF2K) protein, which regulates tumor growth, chemoresistance, and tumor immunosurveillance. Moreover, exogenous administration of miRNA-22, loaded in nanoparticles to prevent degradation and improve tumor delivery (termed miRNA-22 nanotherapy), to suppress eEF2K production has shown potential as an investigational therapeutic agent in vivo. Methods To evaluate the translational potential of miRNA-22 nanotherapy, we developed a multiscale mechanistic model, calibrated to published in vivo data and extrapolated to the human scale, to describe and quantify the pharmacokinetics and pharmacodynamics of miRNA-22 in virtual patient populations. Results Our analysis revealed the dose-response relationship, suggested optimal treatment frequency for miRNA-22 nanotherapy, and highlighted key determinants of therapy response, from which combination with immune checkpoint inhibitors was identified as a candidate strategy for improving treatment outcomes. More importantly, drug synergy was identified between miRNA-22 and standard-of-care drugs against TNBC, providing a basis for rational therapeutic combinations for improved response Conclusions The present study highlights the translational potential of miRNA-22 nanotherapy for TNBC in combination with standard-of-care drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available